SCHEMBL25255334

SCHEMBL25255334

CC1(F)C(=O)Nc2cc(Br)ccc21

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.46
KMT2A Q03164 3/20 0.46
CMA1 P23946 1/20 0.43
AHR P35869 1/20 0.43
PIM1 P11309 2/20 0.43
LMNA P02545 3/20 0.40
GAA P10253 3/20 0.40
L3MBTL1 Q9Y468 2/20 0.40
PIM3 Q86V86 1/20 0.39
PIM2 Q9P1W9 1/20 0.39
ALDH1A1 P00352 2/20 0.38
HTR6 P50406 2/20 0.37
AKR1B1 P15121 1/20 0.37
TGM2 P21980 1/20 0.37
CES1 P23141 1/20 0.37
PKM P14618 1/20 0.37
MAPT P10636 2/20 0.36
KDM4E B2RXH2 1/20 0.36
TP53 P04637 1/20 0.36
BRD4 O60885 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16412396 0.81 CMA1 (0.46) MEN1KMT2ACMA1AHRPIM1
SCHEMBL30462531 0.81 CMA1 (0.46) MEN1KMT2ACMA1AHRPIM1
SCHEMBL1223198 0.81 PDK2 (0.55) MEN1KMT2ACMA1AHRPIM1
SCHEMBL29519108 0.81 PDK2 (0.55) MEN1KMT2ACMA1AHRPIM1
SCHEMBL2266416 0.79 PKM (0.47) CMA1AHRHTR6AKR1B1CES1
SCHEMBL2266409 0.79 PKM (0.47) CMA1AHRHTR6AKR1B1CES1
SCHEMBL31440532 0.79 MEN1 (0.52) MEN1KMT2ACMA1AHRPIM1
SCHEMBL19905697 0.79 PKM (0.47) CMA1AHRHTR6AKR1B1CES1
SCHEMBL11829 0.79 MEN1 (0.52) MEN1KMT2ACMA1AHRPIM1
SCHEMBL29502068 0.79 MEN1 (0.52) MEN1KMT2ACMA1AHRPIM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12630516-B2 Compounds NRG THERAPEUTICS LTD. (GB) 2026-05-19 US disclosed
EP-4208442-B1 MPTP INHIBITORS NRG THERAPEUTICS LTD (GB) 2025-10-22 EP disclosed
US-20250179028-A1 ACRYLAMIDE COMPOUNDS NRG THERAPEUTICS LTD (GB) 2025-06-05 US disclosed
EP-4486721-A1 ACRYLAMIDE COMPOUNDS NRG Therapeutics LTD (GB) 2025-01-08 EP disclosed
CN-118804911-A Acrylamide compound NRG治疗有限公司 2024-10-18 CN disclosed
US-20240067614-A1 NOVEL COMPOUNDS NRG THERAPEUTICS LTD. (GB) 2024-02-29 US disclosed
US-20240067614-A1 NOVEL COMPOUNDS NRG THERAPEUTICS LTD. (GB) 2024-02-29 US disclosed
US-20240067614-A1 NOVEL COMPOUNDS NRG THERAPEUTICS LTD. (GB) 2024-02-29 US disclosed
WO-2023166303-A1 ACRYLAMIDE COMPOUNDS NRG THERAPEUTICS LTD (GB) 2023-09-07 WO disclosed
WO-2023166303-A1 ACRYLAMIDE COMPOUNDS NRG THERAPEUTICS LTD (GB) 2023-09-07 WO disclosed
EP-4208442-A1 NOVEL COMPOUNDS NRG Therapeutics LTD (GB) 2023-07-12 EP disclosed
CN-116096705-A Novel compounds NRG治疗有限公司 2023-05-09 CN disclosed
WO-2022049376-A1 NOVEL COMPOUNDS NRG THERAPEUTICS LTD (GB) 2022-03-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12630516-B2 Compounds CYP4B1, CYP1B1, NR4A1 MEN1 1126/4885KMT2A 761/4885CMA1 2165/4885
US-20240067614-A1 NOVEL COMPOUNDS CYP11B1, CYP11B2, CXCR2 MEN1 661/4885KMT2A 4448/4885CMA1 1525/4885
US-20250179028-A1 ACRYLAMIDE COMPOUNDS ACR, CCNI, FANCI MEN1 699/4885KMT2A 3787/4885CMA1 3861/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.